Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Background: Pneumococcal disease remains a public health priority in adults. Previous studies have suggested that administration of pneumococcal polysaccharide vaccine or pneumococcal conjugate vaccine within three years following receipt of PPV23 was associated with increased reactogenicity and red...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Hum Vaccin Immunother
Główni autorzy: Peterson, James T., Stacey, Helen L., MacNair, John E., Li, Jianing, Hartzel, Jonathan S., Sterling, Tina M., Benner, Patrice, Tamms, Gretchen M., Musey, Luwy K.
Format: Artigo
Język:Inglês
Wydane: Taylor & Francis 2018
Hasła przedmiotowe:
Research Paper
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6605723/
https://ncbi.nlm.nih.gov/pubmed/30427749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1532250
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy